Comparative Pharmacology
Head-to-head clinical analysis: NALIDIXIC ACID versus NEGGRAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALIDIXIC ACID versus NEGGRAM.
NALIDIXIC ACID vs NEGGRAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nalidixic acid is a first-generation quinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, and repair. It exhibits bactericidal activity primarily against Gram-negative bacteria.
Nalidixic acid is a quinolone antibacterial agent that inhibits bacterial DNA gyrase (topoisomerase II), thereby interfering with DNA replication and repair.
1 g orally every 6 hours for 7-14 days. For uncomplicated urinary tract infections, 1 g orally every 12 hours may be sufficient.
1 g orally four times daily for 7-14 days.
None Documented
None Documented
Terminal half-life is approximately 1-2.5 hours in adults with normal renal function. In patients with renal impairment (CrCl <20 mL/min), half-life may be prolonged to 6-21 hours, requiring dose adjustment.
Clinical Note
moderateNalidixic acid + Digoxin
"Nalidixic acid may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNalidixic acid + Digitoxin
"Nalidixic acid may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNalidixic acid + Deslanoside
"Nalidixic acid may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNalidixic acid + Acetyldigitoxin
"Nalidixic acid may decrease the cardiotoxic activities of Acetyldigitoxin."
1-2 hours in normal renal function (terminal elimination half-life); prolonged to 6-12 hours in severe renal impairment (CrCl <20 mL/min)
Primarily renal (80-90% as unchanged drug and active metabolites, including hydroxynalidixic acid and dicarboxylic acid derivative); minimal biliary (<5%) and fecal (<5%) excretion.
Renal: 85-90% (glomerular filtration and tubular secretion, 80% as unchanged drug, 5-10% as active metabolite 7-hydroxynalidixic acid); fecal: 4-5%
Category C
Category C
Quinolone Antibiotic
Quinolone Antibiotic